EBS
Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.21
−0.72%Margins
Gross margin
41.0%
EBITDA margin
-14.9%
EBIT margin
-20.2%
Net margin
-35.1%
FCF margin
24.2%
-72.8%
Return on equity
-22.9%
Return on assets
-16.0%
Return on invested capital
0.61x
Asset turnover
$170.6M
Cash from operations
$3.43
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2026